CPRX.NASDAQCatalyst Pharmaceuticals, INC
Form 4: Catalyst Pharmaceuticals Executive Del Carmen Reports Stock Transactions
Sentiment:
SEC Form 4 Filing
Chief Commercial Officer Jeffrey Del Carmen reports the vesting of restricted stock units and subsequent tax withholding.
Summary
- Jeffrey Del Carmen, Chief Commercial Officer of Catalyst Pharmaceuticals, reported transactions involving the company's stock on February 14, 2025.
- These transactions included the vesting of 10,667 restricted stock units (RSUs) and the withholding of 3,125 shares to cover applicable taxes.
- Following these transactions, Del Carmen directly owns 30,423 shares of Catalyst Pharmaceuticals common stock and 931,008 restricted stock units.
Sentiment
Score: 5
Explanation: This is a routine filing related to stock transactions, indicating a neutral sentiment.
Key Dates
| Date | Description |
|---|---|
| February 14, 2023 | 1/3rd of restricted stock units vested |
| February 14, 2024 | 1/3rd of restricted stock units vested |
| February 14, 2025 | Final 1/3rd of restricted stock units vested; shares delivered within 60 days |
| February 19, 2025 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.